Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Gracell Raises $209 Million in US IPO for Novel CAR-T Therapies

publication date: Jan 8, 2021

Gracell Biotech of Suzhou completed a $209 million NASDAQ IPO for its next-gen CAR-T treatments. Gracell set out to address the difficulties presented by previous cell therapies, including complex manufacture, lack of off-the-shelf products and the short duration of efficacy. Gracell uses two platforms for discovery: FasTCAR, which manufactures autologous CAR-T products in 22-36 hours (rather than two to six weeks); and TruUCAR, which offers off-the-shelf CAR-T products. Gracell has a market cap of $1.7 billion after climbing 38% in early trading. More details....

Stock Symbol: (NSDQ:GRCL)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
The Ritz-Carlton Shanghai Pudong
March 23-25, 2021